62
Participants
Start Date
September 30, 2012
Primary Completion Date
August 31, 2013
Study Completion Date
August 31, 2013
NNC0114-0006
Two i.v. (intravenous) doses administered 6 weeks apart.
placebo
Two i.v. (intravenous) doses administered 6 weeks apart.
Novo Nordisk Investigational Site, Budapest
Novo Nordisk Investigational Site, Riga
Novo Nordisk Investigational Site, Sofia
Novo Nordisk Investigational Site, Sofia
Novo Nordisk Investigational Site, Sofia
Novo Nordisk Investigational Site, Elche
Novo Nordisk Investigational Site, Szikszó
Novo Nordisk Investigational Site, Plovdiv
Novo Nordisk Investigational Site, Debrecen
Novo Nordisk Investigational Site, Debrecen
Novo Nordisk Investigational Site, Sevlievo
Novo Nordisk Investigational Site, Veszprém
Novo Nordisk Investigational Site, Belgrade
Novo Nordisk Investigational Site, Belgrade
Novo Nordisk Investigational Site, A Coruña
Novo Nordisk Investigational Site, Niška Banja
Novo Nordisk Investigational Site, Seville
Novo Nordisk Investigational Site, Moscow
Novo Nordisk Investigational Site, Yaroslavl
Novo Nordisk Investigational Site, Skt. Petersburg
Novo Nordisk Investigational Site, Skt. Petersburg
Novo Nordisk Investigational Site, Skt Petersburg
Novo Nordisk Investigational Site, Skt Petersburg
Novo Nordisk Investigational Site, Kursk
Novo Nordisk Investigational Site, Kazan'
Novo Nordisk Investigational Site, Bialystok
Novo Nordisk Investigational Site, Bydgoszcz
Novo Nordisk Investigational Site, Bytom
Novo Nordisk Investigational Site, Elblag
Novo Nordisk Investigational Site, Katowice
Novo Nordisk Investigational Site, Poznan
Novo Nordisk Investigational Site, Warsaw
Novo Nordisk Investigational Site, Barcelona
Lead Sponsor
Novo Nordisk A/S
INDUSTRY